Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bill Williams says Bria-IMT presents many cancer-associated antigens, not just one, so it can activate adaptive T cells against multiple mutated tumor clones. He adds the cell-based approach also engages the innate immune system, which can recognize tumors undergoing immune evasion, further limiting cancer's ability to escape.

Related Insights

Most cell therapies target a single antigen on cancer cells. Luminary engineers its cells to recognize three different receptors. The therapy only needs one of the three to be present to work, making it significantly harder for cancer cells to mutate and "escape" the treatment.

Bill Williams says BriaCell further modified its OTS cells to express co-stimulatory molecules and cytokines. In lab studies, these OTS Plus cells activated naive T cells and killed cancer cells on repeated challenges, suggesting stronger and more durable immune activation than just HLA matching alone.

Over 99% of cancer-specific targets are proteins located inside the cell, making them invisible to traditional antibody therapies. DEC-Bio's platform leverages the peptide MHC system, which naturally presents fragments of these internal proteins on the cell surface. This effectively unlocks a vast new library of highly cancer-specific targets.

By killing cancer cells directly within the tumor, the treatment exposes the patient's unique, mutated cancer antigens to their immune system. This effectively trains immune cells to recognize and attack similar cancer cells throughout the body, creating a highly personalized, in-situ vaccine.

To increase safety and efficacy, next-generation CAR-T therapies use "logic-gated" designs. These constructs only activate when they detect the co-expression of multiple antigens—a signature unique to tumor cells—thereby avoiding off-target toxicity on healthy tissues that may express only one of the antigens.

Unlike CAR-T therapies that rely on a limited number of engineered cells, T-cell engagers activate the body's entire T-cell repertoire. This vast pool of effector cells makes exhaustion a negligible issue, as only a small fraction is engaged at any time, ensuring a sustained attack on cancer cells.

The company combines two types of immune cells. One delivers a rapid, powerful initial attack to clear many cancer cells but doesn't persist. The other cell type remains longer to "clean up" any remaining cancerous cells, creating a more comprehensive and durable response.

CAR-T cells are engineered to recognize a single antigen, which tumors can downregulate to escape. In contrast, TIL therapy uses a patient's own T-cells that naturally recognize multiple tumor antigens. This polyclonal attack creates a higher barrier for the cancer to develop resistance compared to a single-target CAR-T therapy.

Administering immunotherapy while the primary tumor and lymph nodes are intact allows them to act as an "in-situ vaccine." This generates a more diverse and powerful systemic immune response against cancer cells throughout the body compared to treating after surgical removal of these antigenic sources.

Unlike antigen-directed therapies like CAR-T that can fail due to tumor heterogeneity, this MSC platform targets shared vulnerabilities across tumor subclones, such as DNA damage and immune suppression. This antigen-agnostic strategy is designed to be effective against diverse and evolving cancers.